tradingkey.logo

RAPT Therapeutics Inc

RAPT
View Detailed Chart

7.840USD

+6.810+661.17%
Close 06/17, 16:00ETQuotes delayed by 15 min
1.03BMarket Cap
LossP/E TTM

RAPT Therapeutics Inc

7.840

+6.810+661.17%
Intraday
1m
30m
1h
D
W
M
D

Today

+661.17%

5 Days

+558.82%

1 Month

+835.00%

6 Months

+832.11%

Year to Date

+396.20%

1 Year

+136.86%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 5 analysts
HOLD
Current Rating
30.000
Target Price
2812.62%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

557
Total
5
Median
6
Average
Company name
Ratings
Analysts
RAPT Therapeutics Inc
RAPT
5
Exact Sciences Corp
EXAS
28
CRISPR Therapeutics AG
CRSP
28
Regeneron Pharmaceuticals Inc
REGN
28
Intellia Therapeutics Inc
NTLA
28
Moderna Inc
MRNA
26
1
2
3
...
112

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

1m
15m
30m
1h
D
W
M
1m
15m
30m
D
Buy
Sell(0)
Neutral(0)
Buy(10)
Indicators
Sell(0)
Neutral(0)
Buy(4)
Indicators
Value
Direction
MACD(12,26,9)
0.926
Buy
RSI(14)
95.295
Overbought
STOCH(KDJ)(9,3,3)
72.319
Buy
ATR(14)
0.623
High Vlolatility
CCI(14)
466.667
Overbought
Williams %R
4.651
Overbought
TRIX(12,20)
3.760
Buy
StochRSI(14)
100.000
Buy
Moving Average
Sell(0)
Neutral(0)
Buy(6)
Indicators
Value
Direction
MA5
2.532
Buy
MA10
1.806
Buy
MA20
1.383
Buy
MA50
1.073
Buy
MA100
1.131
Buy
MA200
1.385
Buy

News

More news coming soon, stay tuned...

Company

RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapies for patients living with inflammatory and immunological diseases. Its lead drug candidate, RPT904, is a half-life extended monoclonal antibody (mAb) designed to bind free human immunoglobin E (IgE), which is being developing for the treatment of food allergy, chronic spontaneous urticaria (CSU) and potentially other inflammatory diseases. The Company’s oncology drug candidate, tivumecirnon, is an oral small-molecule C-C motif chemokine receptor 4 (CCR4) antagonist designed to selectively inhibit the migration of immunosuppressive regulatory T cells (Treg) into tumors.
Ticker SymbolRAPT
CompanyRAPT Therapeutics Inc
CEODr. Brian Wong, M.D., Ph.D.
Websitehttps://rapt.com/
KeyAI